tiprankstipranks
Trending News
More News >
Radnet Inc (RDNT)
NASDAQ:RDNT

Radnet (RDNT) AI Stock Analysis

Compare
397 Followers

Top Page

RDNT

Radnet

(NASDAQ:RDNT)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
$82.00
▲(4.62% Upside)
Radnet's overall stock score is driven by strong earnings call results, showcasing record-breaking revenue and positive guidance. However, financial performance is hindered by profitability and leverage concerns, and technical indicators suggest potential short-term weakness. Valuation remains a challenge due to negative earnings.
Positive Factors
Revenue Growth
Radnet's strong revenue and EBITDA growth indicate robust demand for its services and successful strategic initiatives, supporting long-term business expansion.
Digital Health Expansion
The significant growth in digital health and AI revenues suggests Radnet's successful adaptation to technological advancements, enhancing its competitive edge.
Strategic Partnerships
Expanding partnerships with major players like GE HealthCare can drive innovation and broaden Radnet's service offerings, strengthening its market position.
Negative Factors
High Leverage
High leverage can increase financial risk and limit Radnet's ability to invest in growth opportunities, potentially impacting long-term stability.
Profitability Concerns
Negative profit margins highlight operational challenges and cost pressures, which could hinder Radnet's ability to sustain long-term profitability.
Labor Market Challenges
Labor market challenges can disrupt service delivery and increase operational costs, affecting Radnet's ability to maintain efficient operations.

Radnet (RDNT) vs. SPDR S&P 500 ETF (SPY)

Radnet Business Overview & Revenue Model

Company DescriptionRadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
How the Company Makes MoneyRadnet generates revenue primarily through the provision of diagnostic imaging services to patients, which are often reimbursed by insurance providers, including Medicare and Medicaid. The company operates a fee-for-service model, where it bills patients or their insurance for each imaging procedure performed. Key revenue streams include payments for various imaging modalities such as MRI, CT, and ultrasound services. Additionally, Radnet benefits from strategic partnerships with healthcare providers and payers that facilitate patient referrals and enhance service delivery. The company may also engage in value-based care contracts that incentivize the delivery of cost-effective imaging services, contributing to its overall earnings.

Radnet Earnings Call Summary

Earnings Call Date:Nov 09, 2025
(Q3-2025)
|
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Positive
RadNet, Inc.'s third quarter 2025 performance demonstrated record-breaking revenue and adjusted EBITDA, driven by significant growth in advanced imaging and digital health segments. The company successfully improved reimbursement rates and maintained strong financial liquidity. However, challenges remain in the labor market and the slow adoption of certain programs by commercial payers. Despite these lowlights, the overall sentiment is positive, reflecting robust financial performance and strategic growth initiatives.
Q3-2025 Updates
Positive Updates
Record-Breaking Revenue and Adjusted EBITDA
Revenue increased 13.4% and adjusted EBITDA increased 15.2% relative to last year's third quarter, with a 26 basis point improvement in adjusted EBITDA margins.
Advanced Imaging Growth
Advanced imaging increased 13% on an aggregate basis and 9.9% on a same-center basis compared to last year's third quarter.
Digital Health Expansion
Digital health revenue increased 51.6% from last year's third quarter, with AI revenue growing 112%. The acquisition of iCAD contributed to this growth.
Reimbursement Rate Improvements
Successful in receiving rate increases from many commercial and capitated payers, with some capitated contracts converted to higher-paying fee-for-service relationships.
Strong Financial Liquidity
Cash balance was $804.7 million with a net debt to adjusted EBITDA ratio of approximately 1.0.
PET CT Volume Surge
PET CT volume increased 21.1% from last year's third quarter, driven by prostate imaging and amyloid brain studies for Alzheimer's.
Negative Updates
Labor Market Challenges
Continued challenges in hiring and retaining radiology technologists, impacting operations despite some stabilization.
Slow Adoption of EBCD by Commercial Payers
While there is progress, commercial payers are slow to adopt coverage for the EBCD breast cancer screening program.
Medicare Reimbursement Cuts History
Over the last four years, RadNet, Inc. absorbed over $35 million in annual cuts from Medicare physician fee schedule.
Company Guidance
During the RadNet, Inc. third quarter 2025 financial results conference call, the company reported record quarterly revenue and adjusted EBITDA, which exceeded internal expectations. Revenue increased by 13.4%, while adjusted EBITDA rose by 15.2% compared to the same period last year, with a 26 basis point improvement in adjusted EBITDA margins. Advanced imaging was a significant driver, with a 13% aggregate increase and a 9.9% increase on a same-center basis. The company highlighted improvements in reimbursement rates, with notable increases from commercial and capitated payers. Additionally, digital health revenue surged by 51.6%, partly due to the acquisition of iCAD, and AI-related revenue within digital health grew by 112%. As a result of the strong performance, RadNet, Inc. increased its full-year 2025 guidance for revenue and adjusted EBITDA, reflecting continued positive industry trends and successful strategic initiatives.

Radnet Financial Statement Overview

Summary
Radnet demonstrates moderate revenue growth and strong cash flow generation, but profitability and leverage remain concerns. The company faces challenges in maintaining margins and managing debt levels, which could impact future financial stability.
Income Statement
Radnet's income statement shows moderate revenue growth with a 3.24% increase in TTM, but profitability is a concern with a negative net profit margin of -0.65%. The gross profit margin has decreased from previous years, indicating rising costs or pricing pressures. EBIT and EBITDA margins have also declined, reflecting operational challenges.
Balance Sheet
The balance sheet reveals a high debt-to-equity ratio of 1.75, indicating significant leverage, though it has improved from prior years. Return on equity is negative, suggesting inefficiencies in generating returns for shareholders. The equity ratio is relatively stable, but the high leverage poses risks.
Cash Flow
Cash flow analysis shows strong free cash flow growth of 95.27% in TTM, indicating improved cash generation. The operating cash flow to net income ratio is healthy, but the free cash flow to net income ratio suggests that cash flow is not fully translating into profitability. Overall, cash flow management appears robust.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.97B1.83B1.62B1.43B1.32B1.07B
Gross Profit225.22M249.12M221.39M165.72M191.80M105.94M
EBITDA239.79M262.55M292.79M278.53M278.37M199.74M
Net Income-12.71M2.79M3.04M10.65M24.73M-14.84M
Balance Sheet
Total Assets3.67B3.29B2.69B2.43B2.06B1.79B
Cash, Cash Equivalents and Short-Term Investments804.72M740.02M342.57M127.83M134.61M102.02M
Total Debt1.85B1.73B1.49B1.51B1.40B1.18B
Total Liabilities2.35B2.15B1.88B1.94B1.71B1.53B
Stockholders Equity1.06B902.31M630.70M333.00M228.90M165.74M
Cash Flow
Free Cash Flow52.06M44.95M44.26M-103.00M-71.20M108.32M
Operating Cash Flow257.19M233.02M220.86M146.42M149.49M233.76M
Investing Cash Flow-278.74M-233.07M-201.47M-246.95M-221.51M-126.24M
Financing Cash Flow77.48M397.95M195.63M93.65M104.67M-45.56M

Radnet Technical Analysis

Technical Analysis Sentiment
Positive
Last Price78.38
Price Trends
50DMA
76.92
Positive
100DMA
75.73
Positive
200DMA
65.66
Positive
Market Momentum
MACD
-0.32
Negative
RSI
58.38
Neutral
STOCH
87.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDNT, the sentiment is Positive. The current price of 78.38 is above the 20-day moving average (MA) of 74.02, above the 50-day MA of 76.92, and above the 200-day MA of 65.66, indicating a bullish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 58.38 is Neutral, neither overbought nor oversold. The STOCH value of 87.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDNT.

Radnet Risk Analysis

Radnet disclosed 44 risk factors in its most recent earnings report. Radnet reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Radnet Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$19.30B-19.14-34.54%14.47%-353.69%
69
Neutral
$5.34B97.4610.86%2.67%-21.96%
67
Neutral
$11.68B50.863.04%0.29%3.37%-18.80%
63
Neutral
$5.98B-440.83-1.30%11.09%-165.89%
56
Neutral
$1.60B-3.50-39.71%-2.77%-4327.53%
55
Neutral
$1.64B-14.45-12.99%10.10%-44.29%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RDNT
Radnet
78.38
9.60
13.96%
EXAS
Exact Sciences
101.78
45.28
80.14%
NEOG
Neogen
9.71
-2.65
-21.44%
RVTY
Revvity
101.71
-14.38
-12.39%
NEO
NeoGenomics
12.83
-1.94
-13.13%
SHC
Sotera Health
18.81
5.70
43.48%

Radnet Corporate Events

Regulatory Filings and Compliance
RadNet Registers Shares for Resale with SEC
Neutral
Oct 21, 2025

On October 21, 2025, RadNet, Inc. filed a prospectus supplement with the SEC to register for resale up to 59,444 shares of its common stock. This move involves the opinion of Reed Smith LLP on the legality of the securities, potentially impacting the company’s market operations by providing liquidity options for selling stockholders.

The most recent analyst rating on (RDNT) stock is a Buy with a $92.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 20, 2025